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Abstract
The interaction between cancer cells and molecular cues provided by tumor stromal cells plays a crucial role in cancer
growth and progression. We have recently reported that the outcome of interaction between tumor cells and stromal
cells is dependent on the gene expression signature of tumor cells. In the current study, we observed that several
cancer cell lines, e.g., MCF7 breast cancer line, exhibited growth advantage when cultured in the presence of
conditioned media (CM) derived from human bone marrow stromal stem cells (hBMSCs). Regarding the underlying
molecular mechanism, we have identiﬁed CXCR7 as highly expressed by MCF7 cells and that it mediated the
enhanced growth in response to hBMSC CM. Regarding the clinical relevance, we found an inverse correlation
between the level of tumor gene expression of CXCR7 in bladder, breast, cervical, kidney, liver, lung, pancreatic,
stomach, and uterine cancers, and patients’ overall survival. Interestingly, signiﬁcant positive correlation between
CXCR7 and CXCL12 gene expression (Pearson= 0.3, p= 2.0 × 10–16) was observed in breast cancer patients,
suggesting a biological role for the CXCR7/CXCL12 genetic circuit in breast cancer biology. Our data provide insight
into the molecular mechanisms by which stromal-derived microenvironmental cues mediate CXCR7 signaling and
growth enhancement of breast cancer cells. Therapeutic targeting of this circuit might provide novel therapeutic
opportunity for breast cancer.
Introduction
Carcinogenesis is a complex process resulting from an
interplay between malignant cells and microenviron-
mental cues, including extracellular matrix, endothelial
cells, pericytes, immune inﬁltrating cells, and carcinoma-
associated ﬁbroblasts (CAFs)1. This interaction con-
tributes to tumor growth, invasion, and metastasis.
Among the tumor microenvironment components, the
role of CAFs in cancer development is an area of intensive
investigation. A number of studies have suggested that
CAFs are derived from mesenchymal (stromal) stem cells
(MSCs), which are multipotent stem cells present within
the stroma of bone marrow and other organs2. The pre-
cise role of CAFs or MSCs in cancer development and
progression remains controversial3,4. Our recent experi-
mental studies suggested reciprocal interaction between
cancer cells and MSCs5,6. In a co-culture system, we
observed that the effects of human bone marrow-derived
MSCs (hBMSCs) on cancer cells were largely dependent
on the expression of IL1β and CDH1 by tumor cells6.
However, the exact molecular factors secreted by
hBMSCs and their cognate receptors that promote cancer
growth remained largely unknown.
Chemokines and their receptors represent a family of
signaling molecules that may play a role in breast cancer
progression. Karnoub et al. reported a role for BMSC-
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derived C-C Motif Chemokine Ligand 5 in promoting
breast cancer metastasis to the lung7. Similarly, secretion
of stromal cell-derived factor 1 (SDF1, also known as C-
X-C Motif Chemokine Ligand 12 (CXCL12)) by BMSCs
has been implicated in bone metastases of breast cancer
cells8. However, there are limited data on the effect of
hBMSCs-derived factors on tumor growth. Herein, we
performed a systematic approach to assess the role of
secreted factors from hBMSCs in tumor growth in vitro
and identiﬁed C-X-C Chemokine Receptor Type 7
(CXCR7) expressed by tumor cells as a key receptor
driving cancer cell proliferation and survival.
Results
Effect of hBMSC-conditioned media (MCM) on in vitro
cancer cell growth
To assess the effect of MCM on tumor cell growth,
tumor cell lines were cultured (day 0) in the presence of
MCM control fresh medium (FM). Both MCM and FM
were supplemented with 1% fetal bovine serum (FBS). We
examined cell growth in cancer cells on day 2, day 4, and
day 6 post exposure. Qualitative analysis revealed tumor
cells cultured in MCM exhibited enhanced cell pro-
liferation and reached conﬂuency at an earlier time point
compared to cells cultured in FM (Fig. 1). In particular,
MCF7 exhibited the most pronounced response (Fig. 1b).
Secreted factors from hBMSC exhibited variable effects on
different tumor cell lines
To rule out the possibility that the observed enhanced
cell proliferation is mediated by general nonspeciﬁc fac-
tors released by mammalian cells, cancer cells were cul-
tured under three different conditions: (i) in the presence
of MCM derived from hBMSC, (ii) in the presence of own
conditioned media (CM) (tumor conditioned medium)
(TCM), or (iii) under FM. Cell viability was assessed using
the alamarBlue assay on days 2, 4, and 6. As shown in Fig.
2, MDA-MB-231, PC-3, and HT-29 grew better when
cultured in their own TCM (Fig. 2a–e). Although statis-
tically signiﬁcant, the effect of MCM on the growth of
MDA-MB-231 and HT-29 on day 2 was modest. MDA-
MB-468 grew equally well in their own TCM as compared
to MCM (Fig. 2e). Interestingly, MCF7, and to a lesser
extent FaDu on days 4 and 6, grew better in MCM
compared to own TCM (Fig. 2a, b). Overall, all cell lines
grew better in MCM compared to FM. In order to con-
ﬁrm these ﬁndings, we employed the co-culture trans-well
assay experiment, where we cultured tumor cells in the
lower chamber and hBMSC, tumor cells, or just media in
the upper chamber. Tumor cells were included in the
upper chamber in each experimental group to compen-
sate for the total number of cells and to eliminate possible
effects of general factors released by mammalian cells in a
nonspeciﬁc manner. The two chambers are separated by a
semipermeable membrane (pore size 0.4 µm) which
allows only small molecules to pass through. MCF7 and
MDA-MB-231 grew better under MCM condition
(Fig. 3b, c), while PC-3 grew equally under their own
TCM or MCM (Fig. 3d). No promoting effects of TCM or
MCM on the growth of HT-29 and MDA-MB-468 were
observed (Fig. 3e, f), while a modest growth-promoting
effect of TCM and MCM was observed on FaDu cells,
although it was not statistically signiﬁcant (Fig. 3a). Taken
together, our data revealed general promoting effects of
MCM on the growth of MCF7, MDA-MB-231, PC-3, and
FaDu cells.
CXCR7 plays an important role in mediating the promoting
effects of hBMSCs on MCF7 cells
In order to identify potential surface receptors
expressed on tumor cells that mediated the growth
enhancement effects of MCM, we compared molecular
signatures obtained from global gene expression analysis,
between the tumor cell lines that were responsive to
MCM (MCF7, FaDu, MDA-MB-231, and PC-3) and the
nonresponsive cell lines (HT-29 and MDA-MB-468).
Hierarchical clustering based on differentially expressed
genes between the two groups is depicted in Fig. 4a. The
top 100 upregulated genes in the responder group are
shown in Supplementary Table 1. Interestingly, we
observed that CXCR7 was upregulated >16.0 folds in the
responder group compared to the nonresponders group.
CXCR7, also known as ACKR3, is a chemokine receptor
that binds to CXCL11 and CXCL12 (SDF1), while
CXCR4 homodimer binds only to CXCL129. Expression
of CXCR7, but not CXCR4, correlated with the cancer
cell response to MCM (Fig. 4b).
Previous studies have suggested a role for SDF1/
CXCL12 and its receptor CXCR4 in regulating cell
migration and survival10, and a role for CXCR7 in med-
iating cancer tumor survival, and development11. Thus,
we investigated the role of CXCR7 signaling in promoting
tumor cell survival. Since MCF7 expressed the highest
levels of CXCR7 (Fig. 4b), it was employed in the sub-
sequent experiments. Incubating MCF7 with exogenous
CXCL12 (SDF1) promoted cell growth and these effects
were partially abolished by cotreatment with CXCR4
(WZ811) small-molecule inhibitor (Fig. 4c). Interestingly,
MCM promoted MCF7 proliferation, which was not
affected by CXCR4 inhibition (Fig. 4b). siRNA-mediated
inhibition of CXCR7 expression diminished the growth
enhancement effect of MCM, suggesting that signaling via
CXCR7 is a regulatory mechanism promoting MCF7
growth in response to secreted factors present within
MCM. To determine the clinical relevance of our obser-
vations, interrogation of the expression of CXCR7 in
bladder, breast, cervical, kidney, liver, lung, pancreatic,
stomach, and uterine cancers revealed signiﬁcant poor
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overall survival in patients with tumors exhibiting ele-
vated gene expression levels of CXCR7 (Fig. 5). Network
analysis on the cancer genome atlas (TCGA) breast can-
cer dataset revealed interaction between CXCL12 and
CXCR7 (ACKR3), and a number of G-protein family
members (GNG5, GNB4, GNB2, GNG12, GNG7,
GNGT1, and GNAI3, Fig. 6a). Signiﬁcant correlation
between CXCR7 and CXCL12 was also observed in the
same patient cohort, suggesting a regulatory role for
CXCR7 and CXCL12 in breast cancer biology (Fig. 6b).
Schema depicting the role of hBMSCs in promoting
tumor cells via CXCR7 signaling is illustrated in Fig. 6c.
Discussion
Identiﬁcation of factors regulating the interaction
between cancer cells and microenvironment is an area of
intensive investigation as it provides understanding of
cancer development as well as targets for therapy. In this
paper, we have demonstrated that factors secreted by
stromal cells regulate cell proliferation of cancer cells and
identiﬁed signaling through chemokine receptor CXCR7
as a possible mechanism.
Malignant tumors are composed of a multitude of cell
types in addition to the malignant cells, and that include
stromal cells, also known cancer-associated ﬁbroblasts.
Conﬂicting data exist in the literature regarding the pre-
cise role of stromal cells in cancer development and
progression7,12. We have previously proposed that the
discrepancy observed in the published results may be
explained by differences in cancer type, as we observed
that the interaction between tumor cells and stromal cells
is dependent on the gene expression signature of tumor
cells. In addition, we have identiﬁed IL1β and CDH1
expression by tumor cells as predictive markers for this
interaction5,6.
We observed that cancer cell lines vary in the degree of
responsiveness in terms of enhanced cell proliferation
when exposed to CM derived from stromal cells. Inter-
estingly, MCF7 breast cancer cell line exhibited the most
pronounced response. These data corroborate our pre-
vious observations demonstrating increased cell growth of
MCF7 cells when cocultured with hBMSCs in vitro6. Our
data suggest that cancer cell–stromal cell interaction is
cell type speciﬁc and dependent not only on the factors
Fig. 1 Effect of hBMSC-derived conditioned media on tumor growth. Bright ﬁeld (upper panels) images of FaDu, MCF7, MDA-MB-231, PC-3, HT-
29, and MDA-MB-468 tumor cell lines cultured in MCM or FM for 2, 4, or 6 days (10×). Representative image of H and E-stained tumor cells cultured in
MCM or FM (lower panels). Images were taken on day 6 (20× (left) and 60× (right) panel). MCM human bone marrow stromal stem cells conditioned
media, FM fresh media
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Fig. 2 Effect of hBMSC-derived conditioned media on tumor viability. FaDu, MCF7, MDA-MB-231, PC-3, HT-29, and MDA-MB-468 tumor cells
were cultured in FM, TCM, or MCM for 2, 4, and 6 days. Cell viability on the indicated days was assessed using alamarBlue. Data are presented as
mean ± S.E.M. from a minimum of three experiments, n ≥ 20. *P ≤ 0.05, **P ≤ 0.005, ***P ≤ 0.0005. p values were calculated using two-tailed Student
test with equal variance. Black bars indicate compared experimental groups. MCM human bone marrow stromal stem cells conditioned media, TCM
tumor-derived conditioned media, FM fresh media
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Fig. 3 The effect of secreted factors from hBMSCs on tumor growth using the co-culture system. Cell viability of the indicated tumor cell line
cultured under different experimental conditions using the transwell system (0.4 µm). Tumor cells were cultured in the lower chamber, while the
other treatment was in the upper chamber. Cell viability was assessed using alamarBlue assay on day 6. Data are presented as mean ± S.E.M. from a
minimum of three experiments, n ≥ 40. *P ≤ 0.05, **P ≤0.005, ***P≤0.0005. p values were calculated using two-tailed Student test with equal variance.
Black bars indicate compared experimental groups
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secreted by stromal cells, but also on the biological
characteristics of cancer cells.
In order to identify the possible mechanism for differ-
ences in responsiveness to conditioned medium of stro-
mal cells between different cancer cell types, we examined
the molecular signature of cancer cells by using global
gene expression analysis. We identiﬁed CXCR7 as highly
expressed in MCF7 cells and as a possible mediator of the
enhanced cell growth of MCF7 in response to stromal cell
CM. Previous studies have examined the role of chemo-
kine receptors in breast cancer biology. MCF7 and HT-29
(a colon cancer cell line) expressed similar levels of
CXCR4, but only MCF7 expressed higher levels of
CXCR7, which correlated with enhanced cell growth
advantage in response to stromal cell CM. Also, signaling
via CXCR7 has been reported to promote cancer cell
growth11. At a molecular level, CXCR4 binds to CXCL12/
SDF-1, whereas CXCR7 homodimer and CXCR7/CXCR4
heterodimer bind to both CXCL11 and CXCL12/SDF-1.
We have previously reported that stromal cells express
CXCL12, but not CXCL1113. Our loss-of-function studies
showed that inhibition of CXCR7, but not CXCR4, was
able to abolish the observed increase in cell proliferation
in MCF7 cells, suggesting that CXCR7/CXCL12 genetic
circuit regulates the growth responses in MCF7 cells.
Our ﬁndings have clinical relevance, as shown by our
survival analysis of a cohort of cancer patients with dif-
ferent types of cancers. Levels of gene expression of
CXCR7 were positively correlated to increased overall
mortality across different cancer types. Similar to our
Fig. 4 Gene expression analysis of tumor cell lines as a function of response to hBMSC-derived CM. a Hierarchical clustering based on
differentially expressed genes between tumor cell lines that exhibited growth advantage (MCF7, FaDu, MDA-MB-231, and PC-3) compared to those
that did not exhibit growth advantage (HT-29 and MDA-MB-468). b Bar chart depicting the expression of CXCR7 and CXCR4 on the indicated tumor
cell lines. c Effect of inhibition of CXCR4 (using WZ811) or inhibition of CXCR7 on tumor cell growth in the presence of recombinant CXCL12 (SDF1)
or hBMSC-derived CM. Data are presented as mean ± S.E.M. from three experiments
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ﬁndings, a recent meta-analysis demonstrated that high
expression of CXCR7 is associated with higher risk of
lymph node metastasis (LNM), higher tumor grade,
poorer overall survival (OS), and shorter recurrence-free
survival, across multiple cancer types14. These ﬁndings
suggest that CXCR7 expression can be employed as a
prognostic marker for multiple cancer types. Future
longitudinal clinical studies are needed to corroborate the
prognostic value of CXCR7 expression and to provide a
quantitative estimate of its predictive value. Also, phar-
macological targeting of CXCR7 signaling represents a
possible approach for breast cancer therapy.
Conclusion
Our data provide an insight into stromal-derived
microenvironmental cues that interact with cancer cells,
Fig. 5 Expression of CXCR7 is associated with poor prognosis in several cancer types. Kaplan–Meier plots illustrate the duration of overall
survival according to the expression of CXCR7 in bladder, breast, cervical, kidney, liver, lung, pancreatic, stomach, and uterine cancer. Log-rank test
was used for curve comparison
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and identify CXCR7 signaling as an important cancer cell
growth-promoting factor and that tumor tissue expres-
sion level is an unfavorable prognostic marker in breast
and several other cancer types.
Materials and methods
Cell lines and culture
Cell lines used in the current study covered a broad
spectrum of cancer types, including breast (MDA-MB-
231, MDA-MB-468, MCF7), colon (HT-29), head and
neck (FaDu), and prostate (PC-3). Tumor cell lines were
purchased from CLS Cell Lines Service GmbH (Eppel-
heim, Germany) or American Type Culture Collection
(ATCC; Manassas, VA). The well-characterized telomer-
ized hBMSC cell line (hBMSC-TERT) was used as a
model for primary hBMSCs15. All cell lines were main-
tained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 4500 mg/l D-glucose, 4 mM L-gluta-
mine, 110mg/l sodium pyruvate, 10% FBS, 1%
penicillin–streptomycin, and nonessential amino acids
(NEAA).
Preparation of conditioned media
Tumor-derived conditioned media (TCM) and hBMSC
CM (MCM) were prepared using same protocol. Tumor
cells (MDA-MB-231, MDA-MB-468, MCF7; HT-29;
FaDu; and PC-3) and hBMSCs were seeded individually in
six-well plates at 1 × 106/well (4 ml total) in DMEM
supplemented with 10% FBS, 1% NEAA, and 1% peni-
cillin/streptomycin, and incubated at 37 °C and 5% CO2.
At 70–80% conﬂuence, the cells were washed with serum-
free DMEM, and the media were then replaced with fresh
DMEMmedia supplemented with 1% FBS, 1% NEAA, and
1% penicillin/ streptomycin, and incubated at 37 °C and
5% CO2. After 72 h, the media were collected and cen-
trifuged at 300 × g for 10 min to remove any cellular
content and debris, and were then stored at −80 °C until
used.
Fig. 6 CXCR7 and CXCL12-dependent network interactions in breast cancer. a Scatter plot depicting the correlation between CXCR7 and
CXCL12 expression in breast cancer. Pearson and Spearman correlations and associated p values are indicated. b Network analysis illustrating the
interaction between CXCL12, CXCR7, and various members of the G-protein family. c Schema illustrating CXCL12 released by stromal cell to promote
tumor cell survival and proliferation via binding to CXCR7 on breast cancer cells
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Light microscopy
Tumor cells were cultured on chamber slides (Lab-Tek
chamber slides; Nunc, Naperville, IL) at a density of 0.06 ×
106/ml in MCM, TCM, or FM, and then incubated at 37 °C
under 5% CO2. On day 6, cells were ﬁxed in 4% paraf-
ormaldehyde followed by hematoxylin and eosin (H&E)
staining. Stained slides were mounted, covered, and scanned
using ScanScope (×20 or ×60 magniﬁcation). The Nikon®
ECLIPSE Ti-U inverted microscope was used to image the
unstained tumor cells' conﬂuency (×10 magniﬁcation).
Measurement of cell viability
Tumor cells were seeded in 96-well plates at a density of
6 × 103/100 μl/well. Each cell line was seeded on day 0 in
fresh media (FM), TCM, or MCM, and was incubated at
37 °C and 5% CO2 (each experiment was done at least
three times). Cell viability was assessed on day 2, 4, and 6
using the alamarBlue assay. At the indicated time points,
10 μl of alamarBlue reagent (BUF012B; AbD Serotec,
Kidlington, UK) was added to each well and was incu-
bated for 3 h at 37 °C. Subsequently, plates were read
using BioTek Synergy 2 Multi-Mode plate reader (BioTek,
Winooski, VT).
Transwell experiments
Tumor cells were seeded in the lower compartments of
a transwell system (0.4 µm pore size, BD Biosciences) at a
density of 0.06 × 106/1 ml, while the upper inserts con-
tained hBMSCs, same tumor cell line or FM. Cells under
various experimental conditions were incubated at 37 °C
and 5% CO2. On day 6, cell viability was assessed using
alamarBlue as described above.
Transfection and small-molecule inhibitor experiments
The validated siRNA targeting human CXCR7 (assay
ID: 109229) and FAM-labeled scrambled control siRNA
(cat no. AM4620) were purchased from Applied Biosys-
tems (Invitrogen, Carlsbad, CA, USA). Transfection was
performed using a reverse transfection approach, as
described before16. Brieﬂy, siRNA at a ﬁnal concentration
of 30 nM was diluted in 50 µl of Opti-MEM (11058-021;
Gibco, Carlsbad, CA, USA), and 1 µl of Lipofectamine
2000 (catalogue no. 52758; Invitrogen) was diluted in
50 µl OPTI-MEM. The diluted siRNA and Lipofectamine
2000 were mixed and incubated at ambient temperature
for 20min. Twenty microliters of transfection mixture
was added to the tissue culture plate, and subsequently
10,000 cells in 60 μl transfection medium (complete
DMEM without antibiotics) were added to each well.
Twenty-four hours later, the transfection cocktail was
replaced with complete DMEM. Small-molecule inhibitor
targeting CXCR4 (WZ811) was purchased from Sell-
eckchem Inc. (Houston, TX) and was used at 1.0 µM.
Survival analysis and bioinformatics
Kaplan–Meier plots for overall survival in different
cancer RNASEQ datasets were conducted as described
before17. Network analysis was conducted as described
before18. Gene expression data for MCF7, FaDU, MDA-
MB-231, PC-3, HT-29, and MDA-MB-468 from the Cell
Line Encyclopedia (CCLE) project were retrieved from the
Gene Expression Omnibus (GEO) depository under
accession number GSE36133. Data were subsequently
analyzed in R as described before19.
Statistical analyses
Statistical analysis and graphing were performed using
Microsoft EXCEL 2016 and GraphPad Prism 6.0 software
(GraphPad software, San Diego, CA, USA). P values were
calculated using the two-tailed t-test and p value < 0.05
was considered signiﬁcant.
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